Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ, Lee J, Knievel K, McVige J, Wang W, Wu Z, Gillard P, Shah D, Blumenfeld AM.
Schwedt TJ, et al. Among authors: gillard p.
J Manag Care Spec Pharm. 2023 Oct;29(10):1119-1128. doi: 10.18553/jmcp.2023.29.10.1119.
J Manag Care Spec Pharm. 2023.
PMID: 37776119
Free PMC article.
After adjusting for potential confounding variables, persistence to onabotA during the 12-month follow-up period was 40.7% vs 27.8% for CGRP mAbs (odds ratio [OR] = 0.683; 95% CI = 0.604-0.768; P < 0.0001). Persistence to erenumab, fremanezumab, and galcanezumab was 25.
…
After adjusting for potential confounding variables, persistence to onabotA during the 12-month follow-up period was 40.7% vs 27.8% for CGRP …